Positron Emission Tomography in Breast Cancer
AbstractGradually, FDG-PET/CT has been strengthening within the diagnostic algorithms of oncological diseases. In many of these, PET/CT has shown to be useful at different stages of the disease: diagnosis, staging or re-staging, treatment response assessment, and recurrence. Some of the advantages of this imaging modality versus CT, MRI, bone scan, mammography, or ultrasound, are based on its great diagnostic capacity since, according to the radiopharmaceutical used, it reflects metabolic changes that often occur before morphological changes and therefore allows us to stage at diagnosis. Moreover, another advantage of this technique is that it allows us to evaluate the whole body so it can be very useful for the detection of distant disease. With regard to breast cancer, FDG-PET/CT has proven to be important when recurrence is suspected or in the evaluation of treatment response. The technological advancement of PET equipment through the development of new detectors and equipment designed specifically for breast imaging, and the development of more specific radiopharmaceuticals for the study of the different biological processes of breast cancer, will allow progress not only in making the diagnosis of the disease at an early stage but also in enabling personalized therapy for patients with breast cancer. View Full-Text
Share & Cite This Article
Vercher-Conejero, J.L.; Pelegrí-Martinez, L.; Lopez-Aznar, D.; Cózar-Santiago, M.P. Positron Emission Tomography in Breast Cancer. Diagnostics 2015, 5, 61-83.
Vercher-Conejero JL, Pelegrí-Martinez L, Lopez-Aznar D, Cózar-Santiago MP. Positron Emission Tomography in Breast Cancer. Diagnostics. 2015; 5(1):61-83.Chicago/Turabian Style
Vercher-Conejero, Jose L.; Pelegrí-Martinez, Laura; Lopez-Aznar, Diego; Cózar-Santiago, María P. 2015. "Positron Emission Tomography in Breast Cancer." Diagnostics 5, no. 1: 61-83.